ZS Pharma Appoints Martin Babler to Board of Directors
February 10, 2015 16:00 ET
|
ZS Pharma
COPPELL, Texas, Feb. 10, 2015 (GLOBE NEWSWIRE) -- ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today...
ZS Pharma to Present at J.P. Morgan Healthcare Conference
January 06, 2015 08:00 ET
|
ZS Pharma
COPPELL, Texas, Jan. 6, 2015 (GLOBE NEWSWIRE) -- ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today...
ZS Pharma Announces Publication of Results From Phase 3 Study of ZS-9 in Patients With Hyperkalemia in the New England Journal of Medicine
November 21, 2014 12:00 ET
|
ZS Pharma
COPPELL, Texas, Nov. 21, 2014 (GLOBE NEWSWIRE) -- ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today...
ZS Pharma Hosts and Webcasts Investor Event
November 19, 2014 18:46 ET
|
ZS Pharma
COPPELL, Texas, Nov. 19, 2014 (GLOBE NEWSWIRE) -- ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today...
ZS Pharma Presents Positive Results From HARMONIZE (ZS004), a Second Phase 3 Clinical Trial of ZS-9 in Patients With Hyperkalemia, at the American Heart Association Scientific Meeting and Announces Simultaneous Publication of Results in JAMA
November 17, 2014 08:00 ET
|
ZS Pharma
COPPELL, Texas, Nov. 17, 2014 (GLOBE NEWSWIRE) -- ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today...
ZS Pharma Reports Third Quarter 2014 Financial Results and Provides ZS-9 Program Update
November 10, 2014 16:00 ET
|
ZS Pharma
COPPELL, Texas, Nov. 10, 2014 (GLOBE NEWSWIRE) -- ZS Pharma, Inc. (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders,...
ZS Pharma Announces Late Breaking Presentation of Phase 3 HARMONIZE (ZS004) Trial Results in Patients With Hyperkalemia at AHA Annual Meeting
November 06, 2014 08:00 ET
|
ZS Pharma
COPPELL, Texas, Nov. 6, 2014 (GLOBE NEWSWIRE) -- ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today...
ZS Pharma Announces Multiple Presentations From ZS003, a Phase 3 Trial of ZS-9, at the American Society of Nephrology Annual Meeting
October 30, 2014 16:00 ET
|
ZS Pharma
COPPELL, Texas, Oct. 30, 2014 (GLOBE NEWSWIRE) -- ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today...
ZS Pharma to Present at the Credit Suisse Annual Healthcare Conference
October 28, 2014 16:00 ET
|
ZS Pharma
COPPELL, Texas, Oct. 28, 2014 (GLOBE NEWSWIRE) -- ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today...
ZS Pharma Announces Positive Top-Line Results From HARMONIZE (ZS004), a Second Phase 3 Clinical Trial of ZS-9 in Patients With Hyperkalemia
September 23, 2014 16:00 ET
|
ZS Pharma
COPPELL, Texas, Sept. 23, 2014 (GLOBE NEWSWIRE) -- ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today...